, [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. IMAGING TRACERS. • Dispose of any unused PYLARIFY in compliance with applicable regulations. PET scans. FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. If you need help understanding your options, enrolling, or managing your plan, a Florida Blue agent is here for you. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. • Dispose of any unused PYLARIFY in compliance with applicable regulations. 117-328), which staved off certain Medicare cuts, CMS updated the CY 2023 conversion factor in January 2023 to $33. We. 05. For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY®. These comments underpin Karnauskas’ Buy rating, which goes alongside a $23 price target, implying shares will gain ~110% over the coming year. Noridian reimburses compounded drugs for use in implanted infusion pumps by multiplying the price per mcg or mg by the total number of mcg or mg of each drug used to refill the pump. (Pylarify™) to section E. PYLARIFY® uses a radioactive tracer called fluorine-18, or 18. 4 million in the prior year period; GAAP fully diluted net loss of $0. Pylarify Sales Spur Price Gains . The PSMA PET scan is a test that can help your doctor learn if and where prostate cancer has spread outside your prostate gland, including to your lymph nodes, other organs, or bones. Dispose of any unused PYLARIFY in compliance with applicable. • Dispose of any unused PYLARIFY in compliance with applicable regulations. Effect of these therapies on performance has not been established. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. A generic version of piflufolastat F 18 is not available. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Billing should be submitted using the appropriate billing form and Procedure code for (1) tumor PET imaging (78811, 78812, or 78813), (2) tumor PET/CT imaging (78814, 78815, or 78816), or (3) for brain imaging (78608) when a dedicated brain PET study was done for brain tumor evaluation. Lantheus Holdings, Inc. Pylarify PET detected at least one positive lesion in at least one body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of these patients. PYLARIFY® (piflufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. PSMA has become an important development in prostate cancer diagnostics. Preparation and Administration. The price without insurance is around $ 21,000. Lantheus Holdings, Inc. For example, shares gapped up 11% in November of last year following the company. 00 thru 2/28/21. See also: Cardiogen-82 side effects in more detail. 7/16/2021. 9% Sodium Chloride Injection, USP. , Nov. 5% of patients within the studies are shown in Table 2. N/A. 9% Sodium Chloride Injection USP. EPS Revisions. . com. By that rationale, other PSMA PET imaging methods, such as Lantheus' Pylarify, which uses F18 instead of gallium-68, seem to fall outside of the labeling language describing appropriate imaging products. Post Administration Instructions. Call 844-339-8514. U. Please enter your ZIP code to locate the nearest imaging site that offers PYLARIFY®. Piflufolastat f-18 is a Radioactive Diagnostic Agent. Ga 68 PSMA-11 and Pylarify (piflufolastat F 18) were approved by the FDA in 2020 and 2021, respectively. Pricing and Coupons * Prices are without insurance: We could not find an exact match for this medicine. 1. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. In May 2021, the U. PYLARIFY PET/CT scan could interpret your results incorrectly. The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 33. Food and Drug Administration approved the use of PyL (PYLARIFY ®) — also known as 18 F-DCFPyL — a positron-emitting imaging agent that. National Minimum Price: $1,539 (Sumter, SC) National Average Price: $2,173: National Maximum Price: $3,984 (Sumter, SC) PET Scan (Skull to Mid-Thigh) Cost Averages Around the Country. However, in 2022 sales skyrocketed to $527. • Gallium Ga-68 PSMA-11: A multiple -dose vial containing 30 mL 18. PYLARIFY is used along with . Trade Name Pylarify Name of Applicant Progenics Pharmaceuticals, Inc. For an administered activity of 370 MBq (10 mCi), the highest-magnitude radiation doses are delivered to the kidneys, liver and spleen: 45. Billing and Coding Guidelines. • Dispose of any unused PYLARIFY in compliance with applicable regulations. However, following an adjustment by Congress in the Consolidated Appropriations Act 2023 (Public Law No. See also: rubidium chloride rb-82 side effects in more detail. PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U. • Assay the dose in a suitable dose calibrator prior to administration. PYLARIFY may be diluted with 0. PYLARIFY AI is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. November 22, 2021 08:30 ET | Source: Lantheus Holdings, Inc. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. 1 year ago • 15 Replies. Lantheus expects their fully diluted adjusted earnings per share to be between $0. DISCOVER THE DIFFERENCE. Tauvid. 9% vs 65. aPROMISE is a PACS platform that offers quantitative analysis and standardized reporting of PSMA PET/CT image assessments. This date may extended up to six months if a. But Ga-68 requires an expensive Ge-68/Ga-68 in-house generator. NORTH BILLERICA, Mass. 4 million in revenue, up 25% year over year, and a net loss of $11. Turning now to earnings. The June 2021 release of Pylarify set in motion a new series of price increases. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent. Pylarify PET-CT scan. fast heartbeat. S. What is the average wholesale price (AWP)? In the United States, the average wholesale price (AWP) is a pharmaceutical term that describes the average price paid by a retailer to buy a drug from the wholesaler. See also: Cardiogen-82 side effects in more detail. Pylarify is labeled with F-18 and homes in on PSMA, a protein that is overexpressed on the surface of more than 90% of. ” For more information, patients can contact the Memorial Cancer Institute at 954-265-4325 or visit PET Imaging Institute of South Florida's Prostate Cancer page. Morris MJ, Rowe SP, Gorin MA, et al. Abstract. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. This article describes the least restrictive coverage possible. Most facilities said that their experience with insurance approval has been hit or miss, but MD Anderson was the only one who told me. Following PYLARIFY® imaging. Email: [email protected] Coupon & Prices - Cost $49 per month Pylarify Coupon & Prices Is your Pylarify medication too expensive? Get notified when Pylarify medication is added to NiceRx. 49 hours. Trial 1 included two groups of. 33 for the second quarter. Medicare did not pay for the Pylarify used in PSMA PET/CT Scan. That was up from roughly $43 million in the latter half of 2021. 45 and $0. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. Product Solutions – Pharmaceutical Products. SPX. 00. 4. It uses prostate-specific membrane antigen (PSMA) receptors on your cells. Highly volatile share price over the past 3 months. 21, 2022, the NC Medicaid and NC Health Choice programs covers piflufolastat F18 injection, for intravenous use (Pylarify) for use in the Physician’s Administered Drug Program (PADP) when billed with HCPCS code A9595 - Piflufolastat f-18, diagnostic, 1 millicurie. ac61418 •. Follow. But, “since alpha particles are at least 1,000 times more potent than beta particles,” says Bander, “when you put the alpha. S. The price without insurance is around $ 21,000. 3. Assay the dose in a suitable dose calibrator prior to administration. BEVERLY TOWER ADVANCED IMAGING CENTER 8750 Wilshire Blvd. Lantheus Holdings, Inc. In. S. 9 million, up 33. Get a $21,000 grant to buy or equip any vehicle with disability-friendly features. Try searching the Price Guide directly. S. As such, the price of ONTRUZANT, a biosimilar to Herceptin, will be established in the U. Welcome to the Lantheus Third Quarter 2023 Financial Results. Call/WhatsApp: +91-9310090915. PYLARIFY may be diluted with 0. The recommended amount of radioactivity to be administered for PET imaging is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) administered as a single bolus intravenous injection. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The collaboration with Novartis directly. PYLARIFY may be diluted with 0. Medicare Supplement Insurance can help cover your out-of-pocket PET scan costs. 6 million, up nearly 12% sequentially from the third quarter. Contact information For media. It was launched in June 2021 and earned $43 million in revenue during that year. 9% Sodium Chloride Injection USP. 19d. NORTH BILLERICA, Mass. 33 for the second quarter. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. IHCP announces coverage of Pylarify Effective April 28, 2023, the Indiana Health Coverage Programs (IHCP) will add coverage for Current Procedural Terminology (CPT®1) code A9595 - Piflufolastat f-18, diagnostic, 1 millicurie. Effective 3/1/21 price states other. 9% Sodium Chloride Injection USP. com has the following PET scan cost averages around the country per some state: Price Range. One supplier is listed for this compound. DJIA. May 26, 2022 at. 71e2149657a0653da6dd8e244c72a94b. 近期，FDA已经批准了Pylarify (piflufolastat F 18)，一种用于前列腺癌患者前列腺特异性膜抗原 (PSMA)阳性病变的正电子发射断层显像 (PET)药物。. Lantheus Holdings. • Assay the dose in a suitable dose calibrator prior to administration. As the levels of PSAINDICATION. Prostate specific membrane antigen (PSMA) is an attractive target for molecular imaging of prostate cancer and several other solid tumors because of its overexpression in prostate carcinoma and tumor neovasculature, respectively. PYLARIFY (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. Worldwide revenue of $102. In the United States, the average wholesale price (AWP) is a pharmaceutical term that describes the average price paid by a retailer to buy a drug from the wholesaler. The product will be available immediately to imaging. 00 - *Effective 10/1/17 AK price at $400, HI $551. Summary of all time highs, changes and price drops for Lantheus Holdings; Historical stock prices; Current Share Price: US$69. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. PYLARIFY ® (piflufolastat F 18) Injection In the U. PYLARIFY ® (piflufolastat F 18) Injection In the U. For men with prostate cancer, PYLARIFY. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated. More than 90% of. Food and Drug Administration (FDA) for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen (PSMA). DULLES, Va. Atlanta, GA $1,650 – $4,300The Performance of the Pylarify PET/CT at disease recurrence following primary local therapy. We reported revenue of $319. Manufacturing, Supply Chain and Distribution Capabilities Deep experience dealing with complex radiopharmaceuticals: Both imaging and therapy radioligands –short-lived and long-lived. Try searching the Price Guide directly. The wholesale acquisition cost for the maximum dose of Locametz is $5,600, while Pluvicto's maximum list price is $255,000. For example, shares gapped up 11% in November of last year following the company’s quarterly report. 50. Food and Drug Administration (FDA) approved two new imaging agents to help make metastatic prostate cancer easier to find. This sample claim form is only an example. Article Text. This is accomplished by development and execution of a territory business strategy to educate the Prostate Cancer (PCa) treating (and referring). 06. NORTH BILLERICA, Mass. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at. PYLARIFY AI™, FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. , a Lantheus company. 2± 0. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. Received the EOB for my Pylarify PSMA scan. About PYLARIFY ® (piflufolastat F 18) Injection PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate. LoginPYLARIFY PET/CT scan could interpret your results incorrectly. S. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer. However, in 2022 sales skyrocketed to $527. Half-life. PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. In May 2023 the FDA approved F-18-flotufolastat. The following reimbursement information applies: Pricing: Maximum fee of $574. The FDA approved PYLARIFY based on evidence from two clinical trials (Trial 1/NCT02981368 and Trial 2/NCT03739684) of 593 male patients with prostate cancer. Medicare did not pay for the Pylarify used in PSMA PET/CT Scan. As the levels of PSAThe recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. The pH of the solution is 4. Aug 1, 2022For information about ordering PYLARIFY® for your imaging site, and how to get started, contact PYLARIFY® Customer Support at 1-800-964-0446 1-800-964-0446. Published online May 27, 2021. I think Kaiser will allow you to also get an mpMRI, which may prove to be useful if your recurrence is intra-prostatic. 01 μg/mCi of. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Pylarify. Pylarify is sponsored by Lantheus Holdings Inc. Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. Getting Ready for Your Pluvicto Treatment Before you get Pluvicto, you will meet with a healthcare provider from the Molecular Imaging and Therapy Service (MITS). Whether it’s time-sensitive radiopharmaceuticals, specialty pharmaceuticals, newly launched generics, or over-the-counter medicines, our products meet the many diverse needs of providers. with suspected recurrence based on. This means that a negative PYLARIFY PET/CT scan does not rule out that you have prostate cancer, and a positive PYLARIFY PET/CT scan does not confirm that you have prostate cancer. The target price would take the PE to about 19. 7909. Diagnosis chevron_right. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. Medicare allowed $1800+ for the PET/CT but zero for the Pylarify. Assay the dose in a suitable dose calibrator prior to administration. Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting. -1. May 16, 2022 08:00 ET | Source: Lantheus Holdings, Inc. Find a plan Or call. Top Rated Oral Presentation details are as follows: Date & Time: Sunday, September 10, 2023, 8:00 am – 9:30 am CET. PYLARIFY generated net sales of $527. 0. 10 PYLARIFY ® (piflufolastat F 18) Injection Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial. 9 mg ethanol in 0. We are raising our full year adjusted EPS to account for the increased revenue estimates. 25 to $1. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. May 16, 2022 08:00 ET | Source: Lantheus Holdings, Inc. Mary Anne Heino: Thank you, Mark, and good morning to everyone. Please call with any questions and ask for the PET/CT Imaging Department: Decatur (217) 876-6600. To qualify for Pluvicto, one needs a positive PSMA PET scan, but. Present and Future Prospects for the. Pylarify is supplied as a 50mL multiple-dose glass vial containing 37 MBq/mL to 2960 MBq/mL (1 mCi/mL to 80 mCi/mL) of piflufolastat F 18. As of December 2021, the US Food and Drug Administration (FDA) has approved two prostate-specific membrane antigen (PSMA) imaging agents, 68 Ga-PSMA-11 (PSMA-11, for use at the University of California at Los Angeles and San Francisco; and a commercial product named Illuccix, Telix Pharmaceuticals, Fishers, IN) and 18 F. As you may know, the FDA only approved 68Ga-PSMA-11 PET to qualify for Pluvicto. Please talk with your doctor about whether a PSA. The product's dosage form is injection and is administered via intravenous form. ac61418. It has 2 main parts, targeted and radioactive. 6 based on expected EPS of $6. PYLARIFY™ (F-18 labeled piflufolastat, Injection) Question: Could you please tell us how to code the new FDA-approved (May 27, 2021) radiopharmaceutical F-18 piflufolastat injection (PYLARIFY™), a PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: • with suspected metastasis who are. PYLARIFY was developed to target PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. The average injected activity was 340 ± 26 MBq (9. 1 million for the third quarter 2021, representing an increase of 15. A sample CMS-1500 claim form for billing PYLARIFY® is provided below. Lantheus Holdings, Inc. S. 63. PETNET Solutions Inc, A Siemens Healthineers Company, reliably delivers PET radiopharmaceuticals via the largest network of cyclotron-equipped radiopharmacies globally. treedown in reply to Tall_Allen 10 months ago. chevron_right. BEVERLY HILLS CA 90211. The collaboration with Novartis directly. Five9 LiveChat Client. , May 28, 2021 /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially manufacturing and distributing PYLARIFY ® (piflufolastat F 18) injection, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography. PYLARIFY AI™, FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans Oral Presentation: Date & Time: June 12, 2022, 3:00 – 4:30 PM PTPYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostateFDB (First Databank) is committed to serving our customers and the healthcare industry by publishing the best available drug and drug pricing information. Assay the dose in a suitable dose calibrator prior to administration. -1. 3 mSv. 9% sodium chloride injection USP. 1-800-995-4219. BEDFORD, Mass. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. The Department of Veterans Affairs (VA), NCO 21- is conducting a market research survey to identify potential qualified sources capable of providing PYLARIFY (piflufolastat F 18) Injection or equal at a fixed price for a period of performance of a base plus 4 option years at San Francisco VA Health Care System, located at 4150 Clement. and STOCKHOLM, Sweden, February 24, 2022— Palette Life Sciences (“Palette”), a global medical device company dedicated to improving prostate radiation therapy outcomes, announced the. This article describes the least restrictive coverage possible. Lantheus describes its PYLARIFY AI product, on the other hand, as “the only FDA-cleared medical device to offer standardized quantitative and accurate reporting” of PSMA PET/CT images, including those achieved using PYLARIFY PET/CT. We offer high-quality, cost-efficient pharmaceuticals. PYLARIFY may be diluted with 0. 9% Sodium Chloride Injection, USP; Assay the dose in a suitable dose calibrator prior to. 50, other states price at $250. LoginThe percentage of participants with at least one true positive lesion identified on PYLARIFY PET imaging and confirmed by the truth standard. The NAICS Category for the award is 325412 - Pharmaceutical Preparation. This handout explains a PET/CT Pylarify PSMA scan. November 24, 2021. 7 million in the same period last year. S. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and. 55, from $34. Pyl is proprietary, whereas Ga-68-PSMA-11 was donated as patent-free. The diagnostic part of the procedure uses 68 Ga PSMA-11 (Locametz®) or 18 F-PSMA-DcPyl (Pylarify®). 36C25522D0055 is a Firm Fixed Price Federal Contract IDV Award. Pylarify (Piflufolastat F 18) at calibration date and time. (shares outstanding times share price) below $2 to $2. Please refer to the map below for the production site nearest you. In addition to clinical drug information, FDB publishes several drug pricing data fields, including: FDB discontinued the publication of Blue Book Average Wholesale Price (AWP) on September. About Pluvicto. PK ! ¾ˆ H [Content_Types]. with suspected recurrence based on elevated serum levels of prostate-specific. The system is intended to be used with images acquired using nuclear medicine (NM) imaging using PSMA PET/CT. Through rigorous analytical and clinical studies, PYLARIFY AI has demonstrated improved consistency, accuracy and efficiency in quantitative assessment of PSMA PET/CT. 28 May, 2021, 07:00 ET. PDF Version. Lantheus receives US FDA approval of PYLARIFY (piflufolistat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. A PET scan is costly, sometimes prohibitively so. Estimated. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. This sample claim form is only an example. In the U. 69 towards any auto purchase with disability-friendly driving features. Welcome! You’re in GoodRx Provider Mode. 5 to 7. Billerica, MA), for. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. S. Call 844-339-8514 844-339-8514 . 0. Abstract. If approved for Europe, PYLCLARI ® (INN: Piflufolastat (18 F) formerly known as [18 F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging. We take pride in our record of having a 99% cyclotron uptime, allowing us to successfully deliver more than 400,000 doses annually, servicing imaging centers from coast-to-coast. PDF Version. Thirty-one out of thirty-four molecules contain at least one heterocyclic ring, and eleven out of thirty-four molecules contain at least one fluorine atom. To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense. $250. For men with prostate cancer, PYLARIFY PET. Compare prices and print coupons for Pylarify (Piflufolastat F 18) and other drugs at CVS, Walgreens, and other pharmacies. 7 mCi). A prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan is a new type of nuclear medicine procedure for men with prostate cancer. S. Last Close Price. 41-1. Sign Up. S&P 500. Save on Pylarify (piflufolastat f 18) prescription medication with Blink Pharmacy. S. The product's dosage form is injection and is administered via intravenous form. Possible errors have been identified in the 01/01/2019 thru 03/01/2019 files. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at. PYLARIFY, approved by the FDA in May 2021, is the first commercially and widely available prostate-specific membrane antigen (PSMA) PET imaging agent. 9% Sodium Chloride Injection, USP. , Sept. If the invoice lists a dose price, you must indicate the number of mCi’s in the dose. The June 2021 release of Pylarify set in motion a new series of price increases. PYLARIFY was developed to target PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. 5 to 7. November 29, 2021 at 8:30 AM EST. PYLARIFY ® (piflufolastat F 18) Injection . 82 USD. 41-1. Session Title: Clinical Oncology Track - TROP Session. [4] The National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have now updated their guidelines to allow use of Pylarify PSMA PET to qualify for Pluvicto (177Lu-PSMA617).